GLP-1 Guide · Updated July 2026

Compounded Semaglutide in 2026: What's Still Legal and How to Get It

The FDA has made major moves to restrict compounded GLP-1 medications. Here's what actually changed, what's still available, and how to access affordable treatment in 2026.

What the FDA Actually Changed

In February 2025, the FDA removed semaglutide from its official drug shortage list. Tirzepatide had already been removed in December 2024. This was a pivotal moment because the shortage designation was what allowed compounding pharmacies to produce these medications at scale.

After removing semaglutide from the shortage list, the FDA gave compounders a 90-day wind-down period. By mid-2025, producing "essentially a copy" of brand-name semaglutide was no longer permitted for most compounding operations.

Then on April 30, 2026, the FDA went further — proposing to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List entirely. If finalized, this would permanently block large-scale outsourcing facilities from compounding these drugs, even if a new shortage were declared in the future.

What's Still Legal: The 503A Pathway

Here's what most headlines miss: the FDA's actions primarily targeted 503B outsourcing facilities — the large-scale compounding operations. The 503A pathway, which covers state-licensed pharmacies filling individual prescriptions, operates under a different legal framework.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed pharmacist can compound a medication for an individual patient based on a valid prescription. This pathway does not depend on shortage list status and was not affected by the FDA's 2025-2026 enforcement actions.

What this means practically: if you have a legitimate prescription from a licensed provider, a 503A pharmacy can still compound semaglutide for you specifically. The key requirements are that the prescription must be patient-specific, and the pharmacy must be properly licensed in your state.

Why Costs Are Still Lower Than Brand-Name

Brand-name Ozempic and Wegovy can cost over $1,000 per month without insurance. Compounded semaglutide through compliant 503A pharmacies and telehealth platforms typically runs between $99 and $300 per month — a fraction of the brand-name price.

This price difference exists because compounded medications don't carry the marketing, patent licensing, and distribution costs that brand-name drugs do. The active ingredient is the same; the economics of production are different.

How to Access Compounded Semaglutide Safely

With the regulatory crackdown, verifying your source is more important than ever. The FDA has reported nearly 1,000 adverse events associated with compounded semaglutide as of May 2026, many linked to dosing errors from unregulated sources.

To protect yourself, make sure your provider requires a legitimate medical consultation before prescribing. The pharmacy filling your prescription should be verifiable through your state's board of pharmacy database. If a provider is offering semaglutide without requiring a prescription or medical evaluation, that's a significant red flag.

Telehealth has become the primary access channel for compounded GLP-1 medications. Licensed providers conduct virtual consultations, write prescriptions when appropriate, and coordinate with compliant compounding pharmacies to ship medication directly to patients.

What to Expect Going Forward

The public comment period on the FDA's proposal to exclude these drugs from the 503B Bulks List closed at the end of June 2026. A final rule could come within months. However, even if the rule is finalized, it would not affect the 503A patient-specific compounding pathway.

The practical outlook: patients who work with compliant telehealth providers and 503A pharmacies should continue to have access to compounded semaglutide. The providers and platforms that survive this regulatory shakeout will be the ones operating within the legal framework — which ultimately benefits patients by filtering out unregulated operators.

For patients currently using or considering compounded GLP-1 medications, the most important step is confirming that your provider and pharmacy are operating through a legitimate, compliant pathway. The medication is still available — you just need to know where to look.

This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication. Regulatory status of compounded GLP-1 medications is subject to change. Information current as of July 2026.